Cover Image

Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Akihito Ogasawara, Ryosuke Ide, Shinsuke Inoue, Renli Teng, Atsuhiro Kawaguchi
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Clinical Pharmacology in Drug Development
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon
by: Akihito Ogasawara, et al.
Published: (2025)

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites
by: Katharina Erb‐Zohar, et al.
Published: (2024)

Bioavailability, Metabolism, and Excretion of [14C]‐Tazemetostat in Patients With B‐Cell Lymphomas or Advanced Solid Tumors
by: Yingxue Chen, et al.
Published: (2025)

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies
by: Yingxue Chen, et al.
Published: (2025)

Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study
by: Aravind Mittur, et al.
Published: (2026)

A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
by: Wei Zhu, et al.
Published: (2026)

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Adults with Renal Impairment
by: Ping Fu, et al.
Published: (2025)

First‐in‐Human Study of Merotocin, a Short‐Acting Peptidic Oxytocin Receptor Agonist for Lactation Support
by: Yu Bagger, et al.
Published: (2025)

Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Vildagliptin in Healthy Chinese Subjects
by: Mengli Tian, et al.
Published: (2024)

Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis
by: Xiaodong Wang, et al.
Published: (2025)

Pharmacokinetic Profile and Comparative Bioavailability of an Oral Fixed‐Dose Combination of Metformin and Acetylsalicylic Acid (Aspirin)
by: Lourdes Garza‐Ocañas, et al.
Published: (2024)

Population Pharmacokinetics Modeling and Simulation of Deutenzalutamide, A Novel Androgen Receptor Antagonist, in Patients With Metastatic Castration‐Resistant Prostate Cancer
by: Yixian Liu, et al.
Published: (2024)

Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label Trial
by: Gerard Greig, et al.
Published: (2026)

Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function
by: Mason W. Freeman, et al.
Published: (2024)

Pharmacokinetic Interaction Among Amlodipine, Losartan, and Chlorthalidone after a Single Oral Administration in Healthy Male Subjects
by: Seol Ju Moon, et al.
Published: (2026)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Neonatal Fc Receptor Inhibitor Rozanolixizumab: An Ethnic Sensitivity Study in Healthy Japanese, Chinese, and White Participants
by: Assem el Baghdady, et al.
Published: (2024)

Pharmacokinetics of Fipaxalparant, a Small‐Molecule Selective Negative Allosteric Modulator of Lysophosphatidic Acid Receptor 1, and the Effect of Food in Healthy Volunteers
by: Yang Song, et al.
Published: (2024)

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a BTLA Agonist Antibody (Venanprubart) in Healthy Participants, Patients with Systemic Lupus Erythematosus, and Patients with Psoriasis: Results From Three Phase 1 Studies
by: Andrew C. Vendel, et al.
Published: (2026)

Pharmacokinetics of Nitazoxanide Dry Suspensions After Single Oral Doses in Healthy Subjects: Food Effects Evaluation and Bioequivalence Study
by: Chenning Zhang, et al.
Published: (2024)

Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2‐Part, Randomized, Phase 1 Study
by: Akira Koibuchi, et al.
Published: (2025)

Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Oral Formulations of Calcium Dobesilate Capsules in Healthy Chinese Volunteers Under Fasting and Fed Conditions
by: Yanrong Wang, et al.
Published: (2024)

Integrating Pharmacogenomic Insights in GLP‐1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management
by: Navodi Sandamini Jayathilaka, et al.
Published: (2025)

Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants
by: Pharavee Jaiprasart, et al.
Published: (2024)

Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib
by: Panli Cardona, et al.
Published: (2024)

Correction to “Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsenin Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses”
Published: (2025)

The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
by: Nila Ganamurali, et al.
Published: (2026)

Pharmacokinetics and Bioequivalence of Vardenafil Hydrochloride in Healthy Chinese Volunteers
by: Sheng He, et al.
Published: (2024)

Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving Opioids
by: Matthew W. Hruska, et al.
Published: (2024)

Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults
by: Greg Rigdon, et al.
Published: (2024)

Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China
by: Junyuan Qi, et al.
Published: (2024)

Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults
by: Mohamed‐Eslam F Mohamed, et al.
Published: (2024)

Bioequivalence and Pharmacokinetic Evaluation of Regorafenib Tablets in Healthy Chinese Volunteers
by: Zhaoyu Wang, et al.
Published: (2024)

Comparison of the Pharmacokinetics of Three Budesonide Formulations in Healthy Chinese Subjects
by: Tengrui Yin, et al.
Published: (2025)

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants
by: Matthias Hoch, et al.
Published: (2025)

Intravenous Ganaxolone: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in Healthy Adults
by: Maciej Gasior, et al.
Published: (2024)

Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates
by: Ronilda D'Cunha, et al.
Published: (2026)

Pharmacokinetics, Bioequivalence, and Safety of Levothyroxine Sodium Tablets in Healthy Chinese Subjects
by: Juan Jin, et al.
Published: (2025)

Population Pharmacokinetics of Butylphthalide Injection in Elderly Chinese Patients With Ischemic Stroke
by: Shu‐Xian Lyu, et al.
Published: (2025)

Pharmacokinetics, Bioequivalence, and Safety of Bromocriptine Mesylate Tablets in Healthy Chinese Subjects
by: Huan Song, et al.
Published: (2025)

Effect of a High‐Fat Meal on the Pharmacokinetics of an Immediate Release Atogepant Tablet
by: Ramesh R. Boinpally, et al.
Published: (2024)